Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2R | P25116 | 15/20 | 0.62 |
| ▸ | RARA | P10276 | 3/20 | 0.32 |
| ▸ | RARB | P10826 | 3/20 | 0.32 |
| ▸ | RARG | P13631 | 3/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12151776 | 0.97 | F2R (0.65) | F2RRARARARBRARGKCNH2 | |
| Bromide SCHEMBL1731552 | 0.97 | F2R (0.64) | F2RRARARARBRARGKCNH2 | |
| Bromide SCHEMBL1732159 | 0.96 | F2R (0.63) | F2RRARARARBRARGKCNH2 | |
| Bromide SCHEMBL1729869 | 0.95 | F2R (0.66) | F2RRARARARBRARGFFAR4 | |
| Bromide SCHEMBL5490285 | 0.94 | F2R (0.65) | F2RRARARARBRARGFFAR4 | |
| Trifluoroacetic Acid SCHEMBL1729320 | 0.92 | F2R (0.65) | F2RRARARARBRARG | |
| Trifluoroacetic Acid SCHEMBL5491057 | 0.91 | F2R (0.69) | F2RRARARARBRARG | |
| SCHEMBL1730675 | 0.91 | F2R (0.59) | F2RRARARARBRARG | |
| Bromide SCHEMBL1732338 | 0.91 | F2R (0.73) | F2RKCNH2FFAR4 | |
| Trifluoroacetic Acid SCHEMBL1732851 | 0.90 | F2R (0.58) | F2RKCNH2FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090022729-A1 | METHODS AND COMPOSITIONS FOR TREATING CARDIAC DYSFUNCTIONS | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2009-01-22 | — | — | US | claimed |
| EP-1391451-B1 | 2-IMINOPYRROLIDINE DERIVATES | EISAI R&D MAN CO LTD (JP) | 2011-11-23 | — | — | EP | disclosed |
| US-20090022729-A1 | METHODS AND COMPOSITIONS FOR TREATING CARDIAC DYSFUNCTIONS | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2009-01-22 | — | — | US | disclosed |
| US-7244730-B2 | 2-iminopyrrolidine derivatives | EISAI CO., LTD (JP) | 2007-07-17 | — | — | US | disclosed |
| US-20050245592-A1 | 2-Iminopyrrolidine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-11-03 | — | — | US | disclosed |
| US-20050004204-A1 | 2-Iminopyrrolidine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-01-06 | — | — | US | disclosed |
| EP-1391451-A1 | 2-IMINOPYRROLIDINE DERIVATES | Eisai Co., Ltd. (JP) | 2004-02-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245592-A1 | 2-Iminopyrrolidine derivatives | H1-2, H1-3, H1-0 | F2R 2290/4885RARA 2536/4885RARB 2657/4885 |
| US-20050004204-A1 | 2-Iminopyrrolidine derivatives | H1-2, H1-3, H1-0 | F2R 2289/4885RARA 2540/4885RARB 2647/4885 |
| US-20090022729-A1 | METHODS AND COMPOSITIONS FOR TREATING CARDIAC DYSFUNCTIONS | TNNI3, MYLK2, FABP3 | F2R 8/4885RARA 3448/4885RARB 2097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.